Molbio Diagnostics Ltd IPO
Healthcare
Price Band
₹768 – ₹807
Lot Size
18
Minimum Bid Quantity
18
Minimum Investment
₹14526
Issue Size
₹939.7Cr
Opens
2026-08-10
Closes
2026-08-12
Listing
17-08-2026
Subscription Status
Qualified Institutional Buyers
186.39 x
Non-Institutional Investor
49.74 x
Retail Individual Investor
12.57 x
Employees
13.02 x
Total
70.05 x
IPO Details
Issue Type
EQUITY
Face Value
₹1
Tick Size
1
ISIN
INE869T01028
Pre-Apply Available
No
Daily Bidding Time
10:00:00 - 17:00:00
About the Company
Molbio Diagnostics Limited is a point-of-care diagnostics company engaged in developing and manufacturing diagnostic technologies for infectious and non-communicable diseases. Its main product is the Truenat platform, a portable molecular diagnostics system comprising the Trueprep nucleic acid extraction device, Truelab real-time PCR analysers, and disease-specific Truenat test kits. As of March 31, 2026, the company offered molecular testing for 30 diseases through 43 assays, including tuberculosis, COVID-19, hepatitis B and C, HIV, and HPV. Through its subsidiaries and collaborations, the company also provides radiology products, digital pathology solutions, and breast health screening devices. Its research and development (R&D) activities are conducted through its wholly owned subsidiary, Bigtec Private Limited, with its R&D unit based in Bengaluru, Karnataka. The company has six manufacturing facilities in India, including two in Goa and others in Bengaluru, Visakhapatnam, and Pune. These facilities manufacture diagnostic devices, test kits, radiology products, and digital pathology scanners.
Pros
- • The company’s Truenat platform covers multiple diseases through a single point-of-care system. As of March 31, 2026, it offered molecular testing for 30 diseases through 43 assays, including TB, COVID-19, hepatitis B and C, HIV, and HPV. The platform can process one, two, or four samples simultaneously.
- • The company has a portable, battery-operated molecular diagnostics platform designed for point-of-care use. Its Truenat system comprises the Trueprep nucleic acid extraction device and Truelab real-time PCR analysers. The company states that the platform can operate in settings with limited laboratory infrastructure, electricity, and space, with a reported turnaround time of approximately 60 minutes.
- • The company has a dedicated R&D setup with a sizable scientific team and a track record of product development. Its wholly owned subsidiary, Bigtec, conducts R&D from Bengaluru. As of March 31, 2026, the R&D team comprised 153 permanent employees, including 136 scientists, while R&D expenditure stood at Rs 87.46 crore in FY2026.
Cons
- • A significant portion of the company’s revenue from sale of finished goods is derived from Indian Central and state governments and international aid agencies, which contributed Rs 84.56%, 87.83%, and 91.60% in FY26, FY25, and FY24, respectively. Any adverse changes in public healthcare policies, reduction in government or aid-agency spending, changes in healthcare programs, or procurement restrictions could adversely affect the company’s business, financial condition, results of operations, and cash flows.
- • The company derives a significant portion of its revenue from a limited number of customers, with its top 10 customers contributing Rs 1,164.73 crore (83.26%), Rs 822.56 crore (83.62%), and Rs 640.28 crore (78.54%) of revenue from the sale of finished goods in FY26, FY25, and FY24, respectively. The company does not have firm commitment agreements with these customers and primarily receives purchase orders periodically. Any loss of these customers, reduction in orders, pricing pressure, or deterioration in their financial condition could adversely affect the company’s business and results of operations.
- • The company derives a significant portion of its revenue from the sale of diagnostic test kits for tuberculosis (TB), which contributed Rs 982.01 crore (70.20%), Rs 679.88 crore (69.11%), and Rs 508.72 crore (62.40%) of revenue from the sale of finished goods in FY26, FY25, and FY24, respectively. Further, TB test kits accounted for 96.02%, 94.78%, and 93.88% of the total test kits sold in these periods. Any decline in demand for TB test kits due to changes in disease prevalence, adoption of alternative diagnostic methods, changes in government policies or TB eradication programs, or supply chain disruptions could adversely affect the company’s business, results of operations, and cash flows.
Get real-time IPO alerts on WhatsApp
Opening reminders • Subscription updates • GMP alerts • Allotment results
Start WhatsApp Alerts